InvestSMART

Resonance Health Limited (ASX:RHT)

ALERT: Price-sensitive ASX Announcement for RHT
Current share price for RHT : $0.047 0.007 (17.50%)+
Announcement
Release
9 Jun 2026 9:43AM
Price at Release
$0.040
Full Release
download
Summary
Resonance Health Limited, an Australian healthcare technology and clinical services company, announced advancements in their MRI Liver Fibrosis Device and provided an update for their FY26 portfolio. The company is developing a multi-parametric MRI device, which aims to provide a non-invasive alternative to liver biopsies for assessing liver fibrosis and inflammation. This device utilizes standard MRI equipment and proprietary algorithms to produce quantitative assessments of fibrosis and inflammation, overcoming limitations of existing methods. Resonance Health’s platform also includes Software-as-a-Medical-Device (SaMD) solutions, which are already in use at over 400 sites globally. The company projects substantial growth driven by the demand for non-invasive diagnostics in the liver disease diagnostics market, which is estimated to reach over $40 billion by 2026. Their liver fibrosis device is positioned to benefit from the increasing need for non-invasive imaging in GLP-1 and MASH therapeutic trials. The company anticipates further revenue growth from this portfolio, with a targeted commercial launch for the liver fibrosis device planned by FY27/8.
Key Points
  • Resonance Health is advancing an MRI Liver Fibrosis Device as a non-invasive alternative to biopsies.
  • The device uses standard MRI with proprietary algorithms to assess fibrosis and inflammation.
  • The liver disease diagnostics market is projected to surpass $40 billion by 2026.
  • Resonance Health's platform includes SaMD solutions operational in over 400 global sites.
  • Significant growth is expected due to demand from GLP-1 and MASH therapeutic trials.
  • The company targets FY27/8 for the commercial launch of the liver fibrosis device.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.